Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.

ABSTRACT:

Objectives

Treatment of Clostridioides difficile infection (CDI) has undergone significant change in recent years with the introduction of fidaxomicin and bezlotoxumab. This study evaluated the cost-effectiveness of fidaxomicin and bezlotoxumab for initial CDI compared with standard therapy with oral vancomycin.

Methods

A Markov model with eight health states was built based on transition probabilities, costs and health utilities derived from literature to evaluate the cost-effectiveness of standard fidaxomicin, bezlotoxumab plus vancomycin, and extended-pulsed fidaxomicin versus standard oral vancomycin over a lifetime horizon from the US societal perspective.

Results

For overall CDI treatment, oral vancomycin had a cost of $39 178 and was associated with a gain of 1

SUBMITTER: Chen J 

PROVIDER: S-EPMC9478885 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature